Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, CA, USA.
Department of Microbiology and Immunology, University of Illinois at Chicago College of Medicine, Chicago, IL, USA.
Sci Rep. 2022 Jun 22;12(1):10581. doi: 10.1038/s41598-022-14241-7.
Type 2 diabetes is the most prevalent endocrine disease in the world, and recently the gut microbiota have become a potential target for its management. Recent studies have illustrated that this disease may predispose individuals to certain microbiome compositions, and treatments like metformin have been shown to change gut microbiota and their associated metabolic pathways. However, given the limitations and side effects associated with pharmaceuticals currently being used for therapy of diabetes, there is a significant need for alternative treatments. In this study, we investigated the effects of a root extract from Rhodiola rosea in a Leptin receptor knockout (db/db) mouse model of type 2 diabetes. Our previous work showed that Rhodiola rosea had anti-inflammatory and gut microbiome-modulating properties, while extending lifespan in several animal models. In this study, treatment with Rhodiola rosea improved fasting blood glucose levels, altered the response to exogenous insulin, and decreased circulating lipopolysaccharide and hepatic C-reactive protein transcript levels. We hypothesize that these changes may in part reflect the modulation of the microbiota, resulting in improved gut barrier integrity and decreasing the translocation of inflammatory biomolecules into the bloodstream. These findings indicate that Rhodiola rosea is an attractive candidate for further research in the management of type 2 diabetes.
2 型糖尿病是世界上最常见的内分泌疾病，最近肠道微生物群已成为其管理的一个潜在目标。最近的研究表明，这种疾病可能使个体容易产生某些微生物组组成，而二甲双胍等治疗方法已被证明可以改变肠道微生物群及其相关代谢途径。然而，鉴于目前用于糖尿病治疗的药物存在的局限性和副作用，人们迫切需要替代治疗方法。在这项研究中，我们研究了红景天根提取物在 2 型糖尿病的瘦素受体敲除（db/db）小鼠模型中的作用。我们之前的工作表明，红景天具有抗炎和调节肠道微生物群的特性，同时在几种动物模型中延长了寿命。在这项研究中，红景天的治疗改善了空腹血糖水平，改变了对外源胰岛素的反应，并降低了循环脂多糖和肝 C 反应蛋白转录水平。我们假设这些变化部分可能反映了微生物群的调节，从而改善了肠道屏障的完整性，并减少了炎症生物分子向血液中的易位。这些发现表明，红景天是进一步研究 2 型糖尿病管理的有吸引力的候选药物。
